Loading clinical trials...
Loading clinical trials...
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects With Heterozygous Familial Hypercholesterolemia
Conditions
Interventions
Evolocumab
Placebo
Locations
39
United States
Research Site
Scottsdale, Arizona, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Camperdown, New South Wales, Australia
Research Site
Perth, Western Australia, Australia
Research Site
Vancouver, British Columbia, Canada
Research Site
London, Ontario, Canada
Start Date
February 7, 2013
Primary Completion Date
November 27, 2013
Completion Date
December 19, 2013
Last Updated
June 17, 2019
NCT06062394
NCT07230730
NCT07334834
NCT07311941
NCT06903897
NCT06055036
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions